On November 12, Uranium fell 5.44% in Regular Trading, trading at $6.9 per share with turnover of $7.2862 million.
The latest identifiable backdrop is continued market attention on the company’s long-term sales agreements with two major U.S. nuclear utilities, although the previously disclosed catalyst had already supported the stock in the prior session and offers limited explanatory power for the current decline.
Under the disclosed agreements, the company is set to deliver 1.1 million pounds of uranium concentrates over six years at prevailing spot market prices while remaining unhedged. That structure improves committed sales visibility and preserves upside to future uranium prices, but the most recent market move suggests the positive effect from that news has weakened on the margin.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments